Innovative Oral SERD Plus Everolimus Therapy Shows Superior Efficacy in Advanced ER+ HER2- Breast Cancer

Highlight

1. Roche’s phase 3 evERA trial reported that giredestrant, a novel oral selective estrogen receptor degrader (SERD) combined with everolimus, significantly reduces disease progression or death risk by 44% in ER-positive, HER2-negative advanced breast cancer patients previously treated with CDK4/6 inhibitors and endocrine therapy.
2. The subgroup of patients harboring ESR1 mutations experienced an even more pronounced risk reduction of 62%, demonstrating enhanced efficacy in a genetically defined population.
3. The combination therapy exhibited a manageable safety profile with no new safety signals identified.
4. Although overall survival data remain immature, early trends favor the giredestrant plus everolimus combination over standard endocrine treatment plus everolimus.

Study Background